Recent topics on podocytes and aldosterone
- PMID: 25499230
- DOI: 10.1053/j.jrn.2014.10.016
Recent topics on podocytes and aldosterone
Abstract
Podocyte injury is a major cause of proteinuria, a core component of chronic kidney disease. We reported that podocyte impairment underlied the early glomerulopathy in animal models of lifestyle-related diseases, such as hypertension and metabolic syndrome. Accumulating evidence suggests that overactivation of the aldosterone-mineralocorticoid receptor (MR) system has harmful effects on podocytes. We found that MR signaling was enhanced in such lifestyle-related diseases with podocyte injury and proteinuria, which were ameliorated by MR antagonist. Subsequent studies revealed that plasma aldosterone concentrations are not always increased in proteinuric conditions with renal MR activation, and the mechanisms of MR overactivation remained elusive. We recently identified a novel mechanism of Rac1-mediated podocyte impairment using RhoGDIα knockout mice; Rac1 potentiates the activity of MR in a ligand-independent manner, thereby accelerating podocyte injury. We demonstrated that the Rac1-MR pathway contributes to the ligand-independent aberrant MR activation in salt-sensitive hypertension and renal injury models. The importance of the RhoGDIα-Rac1-MR pathway in human glomerular disease is underscored by the findings that mutations in RhoGDIαgene cause nephrotic syndrome. Our results provide evidence that the Rac1-MR signal cascade as a novel therapeutic target for chronic kidney disease.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.Clin Exp Nephrol. 2010 Aug;14(4):303-14. doi: 10.1007/s10157-010-0298-8. Epub 2010 Jun 9. Clin Exp Nephrol. 2010. PMID: 20533072 Review.
-
Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.Clin Exp Pharmacol Physiol. 2013 Dec;40(12):929-36. doi: 10.1111/1440-1681.12177. Clin Exp Pharmacol Physiol. 2013. PMID: 24111570 Review.
-
Mineralocorticoid receptor activation in obesity hypertension.Hypertens Res. 2009 Aug;32(8):649-57. doi: 10.1038/hr.2009.86. Epub 2009 Jun 12. Hypertens Res. 2009. PMID: 19521418 Review.
-
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.J Am Soc Nephrol. 2006 Dec;17(12):3438-46. doi: 10.1681/ASN.2006080944. Epub 2006 Nov 2. J Am Soc Nephrol. 2006. PMID: 17082236
-
Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome.Mol Cell Endocrinol. 2012 Mar 24;350(2):273-80. doi: 10.1016/j.mce.2011.07.018. Epub 2011 Jul 27. Mol Cell Endocrinol. 2012. PMID: 21820485 Review.
Cited by
-
RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice.Sci Rep. 2018 Feb 8;8(1):2686. doi: 10.1038/s41598-018-21176-5. Sci Rep. 2018. PMID: 29422652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials